A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease
Phase of Trial: Phase III
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Brimonidine (Primary)
- Indications Graft-versus-host disease
- Focus Registrational; Therapeutic Use
- Sponsors Ocugen
- 08 Nov 2019 According to the Ocugen media release, Ocugen anticipates a statistical review in the first half of 2020 to determine any adjustments to sample size
- 09 Oct 2019 According to the Ocugen media release, top-line results from the trial are expected in the second half of 2020.
- 02 Aug 2019 Planned End Date changed from 1 Jan 2020 to 1 Aug 2020.